Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HER2-negative Breast Cancer × sacituzumab govitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 4 Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 3 Neoplasm Metastasis 3 Brain Neoplasms 3 Salivary Gland Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Metastatic Urothelial Cancer 1 Laryngeal Neoplasms 1 Klatskin Tumor 1 Hypopharyngeal Neoplasms 1 HER2-negative Breast Cancer 1 Glioblastoma 1 Esophageal Squamous Cell Carcinoma 1

Interventions

eribulin 2 Vinorelbine 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡